Would you like to participate ask a question join the surfers in our next episode?

S2-E54.3 – Inside the Patient-Focused Drug Development Meeting: The Advocates’ Priorities

Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green. They discussed the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021. This included the advocates' priorities (both those who spoke in the PFDD session and others like our panelists) for changes in regulatory policy and programs.

In this conversation, the Surfers and the patient/patient advocate guests share divergent opinions about the relative value of drug development vs. support for non-invasive testing as the top advocacy priority. The group wraps up the episode (and this conversation) by discussing the one message each person hopes regulators took from the Patient-Focused Drug Development meeting.

Request Transcript of This Episode
Request Transcript

NASH & Diabetes Podcast and NASH Tsunami Podcast